Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Ribosomal protein S27 pseudogene 24 is a *processed pseudogene* resulting from the retrotransposition of the functional ribosomal protein S27 (RPS27) gene[1][2]. Pseudogenes like RPS27P24 are highly homologous to their parent gene but are typically intronless, lack regulatory sequences necessary for expression, and do not code for a functional protein. Unlike its protein-coding counterpart, RPS27, this pseudogene does not participate in ribosome assembly, protein synthesis, or cellular functions, nor is it associated with any disease or drug interactions. It is included in genome annotations for completeness and evolutionary studies, but it is not considered a biological or therapeutic target[4][7].\nRPS27P24 is *not* a valid molecular target (therapeutic target, receptor, enzyme, etc.), nor does it have documented interactions, functions, or disease relevance[1][2][4][7]. If you seek information on the functional gene, refer to **Ribosomal protein S27 (RPS27)** instead[3][5]. This entry exclusively addresses the pseudogene (RPS27P24), which is not an actionable biological target.
None
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Ribosomal protein S27 pseudogene 24 (RPS27P24).